Patents by Inventor Stanley R. Krystek

Stanley R. Krystek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antagonistic CD40 Monoclonal Antibodies and Uses Thereof
    Publication number: 20240124597
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: August 22, 2023
    Publication date: April 18, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • Antagonistic CD40 monoclonal antibodies and uses thereof
    Patent number: 11926673
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: March 12, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
  • Antagonistic CD40 monoclonal antibodies and uses thereof
    Patent number: 11795231
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: October 24, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
  • Antagonistic CD40 monoclonal antibodies and uses thereof
    Patent number: 11773178
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: October 3, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
  • PRODRUGGABLE ANTIBODIES, PRODRUGS THEREOF, AND METHODS OF USE AND MAKING
    Publication number: 20230295346
    Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
    Type: Application
    Filed: March 9, 2023
    Publication date: September 21, 2023
    Inventors: Stanley R. Krystek, JR., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
  • Prodruggable antibodies, prodrugs thereof, and methods of use and making
    Patent number: 11623965
    Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: April 11, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stanley R. Krystek, Jr., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
  • Fibronectin type III domain proteins with enhanced solubility
    Patent number: 11512124
    Abstract: Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated. Also provided are libraries comprising a plurality of the polypeptides and a method for identifying a polypeptide that binds to a target.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: November 29, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Aaron P. Yamniuk, Stanley R. Krystek
  • ANTI-CTLA4 ANTIBODY PRODRUGGABLE (PROBODY) AT A CDR POSITION
    Publication number: 20220251206
    Abstract: An anti-CTLA4 antibody can be prodrugged by replacement of certain complementarity determining region (CDR) amino acids with a cysteine (Cys), which provides a chemical functionality for attachment of a blocking moiety that can be cleaved at the site of intended action, thus releasing the un-prodrugged antibody.
    Type: Application
    Filed: June 8, 2020
    Publication date: August 11, 2022
    Inventors: Stanley R. KRYSTEK JR., Chetana RAO-NAIK, Gregory D. VITE, Paul E. MORIN, Zheng LIN
  • ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20220169742
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: February 11, 2022
    Publication date: June 2, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, Jr., Akbar NAYEEM, Ginger RAKESTRAW
  • ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20220153856
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20220144962
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: January 19, 2022
    Publication date: May 12, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • Antagonistic CD40 monoclonal antibodies and uses thereof
    Patent number: 11261258
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: March 1, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
  • Antagonistic CD40 monoclonal antibodies and uses in treating immune responses
    Patent number: 11254750
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: February 22, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
  • FIBRONECTIN TYPE III DOMAIN PROTEINS WITH ENHANCED SOLUBILITY
    Publication number: 20210070840
    Abstract: Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated. Also provided are libraries comprising a plurality of the polypeptides and a method for identifying a polypeptide that binds to a target.
    Type: Application
    Filed: August 21, 2020
    Publication date: March 11, 2021
    Inventors: Aaron P. YAMNIUK, Stanley R. KRYSTEK
  • ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20210054090
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 25, 2021
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • Fibronectin type III domain proteins with enhanced solubility
    Patent number: 10787498
    Abstract: Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated. Also provided are libraries comprising a plurality of the polypeptides and a method for identifying a polypeptide that binds to a target.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: September 29, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Aaron P Yamniuk, Stanley R Krystek
  • ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20200157233
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: November 18, 2019
    Publication date: May 21, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies
    Patent number: 10358490
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: July 23, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • PRODRUGGABLE ANTIBODIES, PRODRUGS THEREOF, AND METHODS OF USE AND MAKING
    Publication number: 20190055321
    Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
    Type: Application
    Filed: August 14, 2018
    Publication date: February 21, 2019
    Inventors: Stanley R. Krystek, JR., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
  • IL-17A/F AND IL-23p19 BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20180037645
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: September 1, 2017
    Publication date: February 8, 2018
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty